Oric Pharmaceuticals (ORIC) Institutional Ownership

95.05% of Oric Pharmaceuticals' stock is owned by institutional investors. Learn more on ORIC's institutional investor holdings.

Of the 142 institutional investors that purchased Oric Pharmaceuticals' stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Orbimed Advisors LLC ($2.94M), Paradigm Biocapital Advisors LP ($2.40M), Siren L.L.C. ($1.99M), State Street Corp ($1.85M), Vivo Capital LLC ($1.85M), MPM Bioimpact LLC ($1.80M), and Boxer Capital Management LLC ($1.73M).

Institutional investors have bought a total of 29,789,061 shares in the last 24 months. This purchase volume represents approximately $297.91M in transactions.

Of the 40 institutional investors that sold Oric Pharmaceuticals' stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: EcoR1 Capital LLC ($1.80M), Vivo Capital LLC ($1.28M), Balyasny Asset Management L.P. ($1.06M), JPMorgan Chase & Co. ($1.03M), Orbimed Advisors LLC ($947.83K), Integral Health Asset Management LLC ($350K), and Frazier Life Sciences Management L.P. ($344.86K).

Institutional investors have sold a total of 8,839,202 shares in the last 24 months. This volume of shares sold represents approximately $90.52M in transactions.